|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.00 CAD | -3.16% |
|
+1.69% | +17.83% |
| 05-22 | BioSyent Inc., Q1 2026 Earnings Call, May 14, 2026 | |
| 05-19 | BioSyent Secures Health Canada Nod For Hypothyroidism Oral Solution | MT |
| Market Cap | 172M 123M 106M 99.44M 91.22M 11.72B 174M 1.17B 458M 5.87B 462M 452M 19.41B | P/E 2026 * |
16.9x | P/E 2027 * | 13.9x |
|---|---|---|---|---|---|
| Enterprise Value | 172M 123M 106M 99.44M 91.22M 11.72B 174M 1.17B 458M 5.87B 462M 452M 19.41B | EV / Sales 2026 * |
2.49x | EV / Sales 2027 * | 2.08x |
| Free-Float |
64.14% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioSyent Inc.
| 1 day | -3.16% | ||
| 1 week | +1.69% | ||
| Current month | +1.69% | ||
| 1 month | +4.02% | ||
| 3 months | +2.46% | ||
| 6 months | +17.19% | ||
| Current year | +17.83% |
| 1 week | 14.65 |  | 15.5 |
| 1 month | 14.5 | | 15.5 |
| Current year | 12.25 | | 15.8 |
| 1 year | 10.65 | | 15.8 |
| 3 years | 7.57 | | 15.8 |
| 5 years | 6.24 | | 15.8 |
| 10 years | 3.13 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
Peter Lockhard
BRD | Director/Board Member | 62 | 2002-05-31 |
Stephen Wilton
BRD | Director/Board Member | 65 | 2014-01-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/30/26 | Tax | Executive/Senior Manager | -11,359 | 0.0993% | ||
| 6/30/26 | Option | Chief Technology Officer | -600 | 0.0052% | ||
| 6/30/26 | Buy | Chief Technology Officer | -1,884 | 0.0165% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.16% | +1.69% | +31.00% | +98.68% | 123M | |
| -0.52% | +3.21% | +85.02% | +161.12% | 1,057B | |
| +0.88% | +1.13% | +51.13% | +49.76% | 625B | |
| +0.89% | -1.95% | +23.73% | +63.67% | 435B | |
| +0.71% | +3.87% | +47.45% | +38.68% | 363B | |
| +0.64% | -0.49% | +35.39% | +40.21% | 296B | |
| +0.39% | -5.83% | +8.64% | +9.28% | 249B | |
| +1.51% | +6.69% | +44.34% | +62.47% | 222B | |
| +3.92% | -0.46% | -1.21% | -44.09% | 209B | |
| +1.80% | +2.30% | +20.79% | +65.13% | 165B | |
| Average | +0.86% | +0.95% | +34.63% | +54.49% | 362.09B | |
| Weighted average by Cap. | +1.12% | +1.22% | +48.34% | +75.34% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 69M 49.51M 42.82M 39.99M 36.69M 4.71B 70.1M 469M 184M 2.36B 186M 182M 7.81B | 82.3M 59.05M 51.08M 47.7M 43.76M 5.62B 83.61M 560M 220M 2.82B 222M 217M 9.31B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-07 | $15.00 | -3.16% | 25,601 |
| 26-08-06 | $15.49 | -0.06% | 416 |
| 26-08-05 | $15.50 | +5.80% | 155,935 |
| 26-08-04 | $14.65 | -0.68% | 46,242 |
| 26-07-31 | $14.75 | +0.61% | 3,743 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
15.00CAD
Average target price
18.00CAD
Spread / Average Target
+20.00%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
Select your edition
All financial news and data tailored to specific country editions
